Cuba records breakthrough with world’s first advanced lung cancer vaccine
Cuba has made a significant breakthrough in cancer research with the world’s first therapeutic vaccine for advanced lung cancer.
Developed after over fifteen years of research by experts at the Centre for Molecular Immunology (CIM) in Cuba, the CIMAVAX-EGF vaccine has already provided treatment to over a thousand patients on the Caribbean Island
Experts from CIM say that the CIMAVAX-EGF vaccine stands out for its lack of severe adverse effects and ability to transform advanced cancer into a manageable chronic condition, local media Cuba Si reports.
The vaccine relies on a protein that is epidermal growth factor and related to cell proliferation processes and is also administered post-radiotherapy or chemotherapy, playing a crucial role in controlling tumor growth without the burden of associated toxicity.
Beyond its immediate therapeutic impact, the vaccine also holds the potential for use as a chronic treatment, significantly elevating patients' expectations and enhancing their overall quality of life.
Following its successful registration in Cuba, CIMAVAX-EGF is making strides in other countries, with ongoing evaluations exploring its application in therapies against various tumors, including those affecting the prostate, uterus, and breasts.
This global advancement, was facilitated by a strategic alliance between the Cuban institution and the Roswell Park Cancer Research Center in the United States, Cuba Si reported.
